

Reinhard BÄ¼ttner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1823895/publications.pdf>

Version: 2024-02-01

145
papers

9,579
citations

71102

41
h-index

42399

92
g-index

149
all docs

149
docs citations

149
times ranked

15000
citing authors

#	ARTICLE	IF	CITATIONS
1	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. <i>Journal of Clinical Pathology</i> , 2023, 76, 47-52.	2.0	9
2	Precision medicine in non-small cell lung cancer: Current applications and future directions. <i>Seminars in Cancer Biology</i> , 2022, 84, 184-198.	9.6	106
3	Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort. <i>Head and Neck Pathology</i> , 2022, 16, 394-406.	2.6	7
4	Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X. <i>International Journal of Cancer</i> , 2022, 150, 56-66.	5.1	2
5	Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 76-88.	1.1	37
6	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. <i>Journal of Clinical Pathology</i> , 2022, 75, 416-421.	2.0	6
7	The E3 ligase COP1 promotes ER α signaling and suppresses EMT in breast cancer. <i>Oncogene</i> , 2022, 41, 173-190.	5.9	8
8	Invasive mucinous adenocarcinoma: genetic insights into a lung cancer entity with distinct clinical behavior and genomic features. <i>Modern Pathology</i> , 2022, 35, 138-139.	5.5	3
9	Prevalence of abnormal Pap smear results in inflammatory bowel disease: a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3071-3079.	2.5	3
10	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	2.5	26
11	Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours. <i>British Journal of Cancer</i> , 2022, 126, 937-947.	6.4	8
12	Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. <i>Npj Systems Biology and Applications</i> , 2022, 8, 2.	3.0	0
13	Autophagy-Related Activation of Hepatic Stellate Cells Reduces Cellular miR-29a by Promoting Its Vesicular Secretion. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1701-1716.	4.5	12
14	Molecular Diagnostics of Lung Cancer in Serous Effusion Samples. <i>Journal of Molecular Pathology</i> , 2022, 3, 78-87.	1.2	2
15	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. <i>Lung Cancer</i> , 2022, 168, 10-20.	2.0	6
16	CD74-NRG1 Fusions Are Oncogenic <i>In Vivo</i> and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 821-830.	4.1	4
17	The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1794-1805.	7.2	1
18	Crizotinib in ROS1-rearranged lung cancer (EUCROSS): Updated overall survival.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9078-9078.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Metastatic patterns plus clinical and molecular characteristics of <i>ROS1</i> aberrations in non-small cell lung cancer patients without rearrangements. <i>Journal of Clinical Oncology</i> , 2022, 40, e21117-e21117.	1.6	0
20	Microsatellite instability and sex differences in resectable gastric cancer – A pooled analysis of three European cohorts. <i>European Journal of Cancer</i> , 2022, 173, 95-104.	2.8	9
21	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). <i>Lung Cancer</i> , 2021, 152, 174-184.	2.0	53
22	Tumor budding assessed according to the criteria of the International Tumor Budding Consensus Conference determines prognosis in resected esophageal adenocarcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 393-400.	2.8	13
23	Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence. <i>Lung Cancer</i> , 2021, 151, 91-96.	2.0	5
24	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. <i>Genetics in Medicine</i> , 2021, 23, 705-712.	2.4	28
25	Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains. <i>Clinical Cancer Research</i> , 2021, 27, 1131-1138.	7.0	32
26	GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1031-1040.	2.5	5
27	Value of upper gastrointestinal endoscopy for gastric cancer surveillance in patients with Lynch syndrome. <i>International Journal of Cancer</i> , 2021, 148, 106-114.	5.1	28
28	Data driven precision medicine: who is the driver?. <i>Oncotarget</i> , 2021, 12, 253-254.	1.8	1
29	Awakening of SCHLAFEN 11 by immunohistochemistry: a new biomarker predicting response to chemotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 567-568.	2.8	3
30	Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. <i>BMC Medical Genomics</i> , 2021, 14, 62.	1.5	58
31	Protein loss of SWI/SNF complex core subunits influences prognosis dependent on histological subtypes of intra- and extrahepatic cholangiocarcinoma. <i>Oncology Letters</i> , 2021, 21, 349.	1.8	6
32	The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. <i>Lung Cancer</i> , 2021, 154, 161-175.	2.0	105
33	Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous KrasLSL-G12V Driven Lung Cancer Mouse Model. <i>Pathology and Oncology Research</i> , 2021, 27, 596522.	1.9	1
34	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. <i>European Journal of Cancer</i> , 2021, 148, 124-133.	2.8	11
35	Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 2540.	12.8	295
36	Pericentromeric Satellite III transcripts induce etoposide resistance. <i>Cell Death and Disease</i> , 2021, 12, 530.	6.3	9

#	ARTICLE	IF	CITATIONS
37	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2856.	2.4	11
38	Quality control stress test for deep learning-based diagnostic model in digital pathology. <i>Modern Pathology</i> , 2021, 34, 2098-2108.	5.5	72
39	Early detection of duodenal cancer by upper gastrointestinal endoscopy in Lynch syndrome. <i>International Journal of Cancer</i> , 2021, 149, 2052-2062.	5.1	4
40	Cardiac metastasis causes paradoxical malignant embolism. <i>Cancer Reports</i> , 2021, , e1513.	1.4	2
41	Quantum Cascade Laser-Based Infrared Imaging as a Label-Free and Automated Approach to Determine Mutations in Lung Adenocarcinoma. <i>American Journal of Pathology</i> , 2021, 191, 1269-1280.	3.8	7
42	Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 4300.	3.7	4
43	Shifting Gears in Precision Oncology—Challenges and Opportunities of Integrative Data Analysis. <i>Biomolecules</i> , 2021, 11, 1310.	4.0	3
44	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. <i>Nature Communications</i> , 2021, 12, 5505.	12.8	30
45	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	12.8	237
46	High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer. <i>ERJ Open Research</i> , 2021, 7, 00787-2020.	2.6	2
47	LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma—Potential Biomarkers for Targeted Therapy Concepts. <i>International Journal of Molecular Sciences</i> , 2021, 22, 379.	4.1	24
48	A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 712-712.	1.4	1
49	Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors. <i>Cancers</i> , 2021, 13, 6081.	3.7	9
50	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 102.	5.4	11
51	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. <i>Genetics in Medicine</i> , 2020, 22, 15-25.	2.4	365
52	ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. <i>Leukemia</i> , 2020, 34, 771-786.	7.2	13
53	Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 12.	2.6	35
54	PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis. <i>Translational Oncology</i> , 2020, 13, 157-164.	3.7	29

#	ARTICLE	IF	CITATIONS
55	Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing. <i>Scientific Reports</i> , 2020, 10, 11387.	3.3	33
56	PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5228.	4.1	19
57	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1300-1307.	2.8	9
58	Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival. <i>Scientific Reports</i> , 2020, 10, 18411.	3.3	22
59	Expression Profiling of Extracellular Matrix Genes Reveals Global and Entity-Specific Characteristics in Adenoid Cystic, Mucoepidermoid and Salivary Duct Carcinomas. <i>Cancers</i> , 2020, 12, 2466.	3.7	19
60	Combining biopsy tools improves mutation detection rate in central lung cancer. <i>ERJ Open Research</i> , 2020, 6, 00002-2020.	2.6	0
61	Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5638-5645.	7.0	21
62	Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies. <i>BMC Gastroenterology</i> , 2020, 20, 417.	2.0	23
63	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , 2020, 5, 1-42.	1.2	15
64	Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. <i>Lung Cancer</i> , 2020, 144, 40-48.	2.0	9
65	Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. <i>Cancer Medicine</i> , 2020, 9, 4991-5007.	2.8	14
66	Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091757.	3.2	10
67	The X-linked trichothiodystrophy-causing gene RNF113A links the spliceosome to cell survival upon DNA damage. <i>Nature Communications</i> , 2020, 11, 1270.	12.8	26
68	Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1363-1373.	4.2	26
69	Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2319-2327.	2.5	25
70	Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma. <i>Cancers</i> , 2020, 12, 451.	3.7	7
71	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. <i>Gastroenterology</i> , 2020, 158, 1326-1333.	1.3	60
72	Cell type-specific transcriptomics of esophageal adenocarcinoma as a scalable alternative for single cell transcriptomics. <i>Molecular Oncology</i> , 2020, 14, 1170-1184.	4.6	8

#	ARTICLE	IF	CITATIONS
73	Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study. <i>BMC Cancer</i> , 2020, 20, 460.	2.6	32
74	Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies. <i>Oncology Letters</i> , 2020, 19, 3665-3670.	1.8	13
75	The Scaffolding Protein NEDD9 Regulates Chronic Lymphocytic Leukemia Cell Migration Via the CXCR4 - CXCL12 Axis and Promotes Disease Progression. <i>Blood</i> , 2020, 136, 2-2.	1.4	0
76	First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2019, 8, e1665977.	4.6	21
77	Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 1339-1347.	4.1	16
78	Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 21.	2.0	6
79	Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2019, 127, 285-296.	2.4	39
80	The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. <i>Oncolimmunology</i> , 2019, 8, e1581546.	4.6	59
81	Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 973-982.	4.2	21
82	Bronchoscopic Brushing from Central Lung Cancer – Next Generation Sequencing Results are Reliable. <i>Lung</i> , 2019, 197, 333-337.	3.3	7
83	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	17
84	K-ras Mutation Subtypes in NSCLC and Associated Co-occurring Mutations in Other Oncogenic Pathways. <i>Journal of Thoracic Oncology</i> , 2019, 14, 606-616.	1.1	178
85	Genomic Characterization of TP53 – Wild-Type Esophageal Carcinoma. <i>Translational Oncology</i> , 2019, 12, 154-161.	3.7	8
86	BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – Preliminary results from the SCLC cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8563-8563.	1.6	4
87	Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated report on progression-free and overall survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9066-9066.	1.6	2
88	BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – Preliminary results from the NSCLC cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20550-e20550.	1.6	3
89	Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20682-e20682.	1.6	2
90	Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2018, 9, 727.	12.8	160

#	ARTICLE	IF	CITATIONS
91	LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. <i>Oncogene</i> , 2018, 37, 2746-2756.	5.9	16
92	The landscape of genetic alterations in ameloblastomas relates to clinical features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 807-814.	2.8	46
93	Does volumetric measurement serve as an imaging biomarker for tumor aggressiveness of ameloblastomas?. <i>Oral Oncology</i> , 2018, 78, 16-24.	1.5	5
94	AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer. <i>Oncogene</i> , 2018, 37, 1503-1518.	5.9	26
95	Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	3.0	2
96	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	12.8	107
97	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	12.6	213
98	No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. <i>Gastroenterology</i> , 2018, 155, 1400-1409.e2.	1.3	112
99	Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. <i>Cancer Research</i> , 2018, 78, 4270-4281.	0.9	117
100	Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. <i>Oncogene</i> , 2018, 37, 5682-5693.	5.9	29
101	Copy number variation analysis and targeted NGS in 77 families with suspected Lynch syndrome reveals novel potential causative genes. <i>International Journal of Cancer</i> , 2018, 143, 2800-2813.	5.1	11
102	Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. <i>Genome Medicine</i> , 2018, 10, 55.	8.2	37
103	Comparative proteomics reveals a diagnostic signature for pulmonary head&neck cancer&metastasis. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	41
104	Genetic instability and recurrent <i>MYC</i> amplification in <i>ALK</i> -translocated NSCLC: a central role of <i>TP53</i> mutations. <i>Journal of Pathology</i> , 2018, 246, 67-76.	4.5	52
105	Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFR α wild-type GISTs are rare events. <i>Human Pathology</i> , 2017, 62, 206-214.	2.0	50
106	Mechanisms of Primary Drug Resistance in <i>FGFR1</i> -Amplified Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5527-5536.	7.0	44
107	Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target. <i>Molecular and Clinical Oncology</i> , 2017, 6, 639-642.	1.0	11
108	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	55

#	ARTICLE	IF	CITATIONS
109	Molecular Profiling of Odontogenic Tumors - Pilot Study. <i>Balkan Journal of Dental Medicine</i> , 2017, 21, 112-115.	0.2	2
110	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. <i>Cell Reports</i> , 2017, 20, 2833-2845.	6.4	40
111	Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 225-228.	1.0	7
112	Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS). <i>Hereditary Cancer in Clinical Practice</i> , 2017, 15, 22.	1.5	6
113	Notch signaling triggers the tumor heterogeneity of small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 4884-4888.	1.4	7
114	High protein and mRNA expression levels of TUBB3 (class III β -tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas. <i>Oncotarget</i> , 2017, 8, 115179-115189.	1.8	13
115	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. <i>Modern Pathology</i> , 2016, 29, 1165-1172.	5.5	340
116	B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. <i>Blood</i> , 2016, 127, 2732-2741.	1.4	99
117	STAT3/IRF1 Pathway Activation Sensitizes Cervical Cancer Cells to Chemotherapeutic Drugs. <i>Cancer Research</i> , 2016, 76, 3872-3883.	0.9	43
118	Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. <i>American Journal of Human Genetics</i> , 2016, 99, 337-351.	6.2	198
119	<sc>NOTCH</sc>, <sc>ASCL1</sc>, p53 and <sc>RB</sc> alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. <i>International Journal of Cancer</i> , 2016, 138, 927-938.	5.1	143
120	Unusual Presentation of an Adenocarcinoma of the Lung Metastasizing to the Mandible, Including Molecular Analysis and a Review of the Literature. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016, 74, 2007.e1-2007.e8.	1.2	8
121	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 4837-4847.	7.0	223
122	Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. <i>Gut</i> , 2016, 65, 1296-1305.	12.1	65
123	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. <i>Oncotimmunology</i> , 2016, 5, e1100789.	4.6	45
124	NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 697-705.	2.8	24
125	Loss of the LIM-only protein Fhl2 impairs inflammatory reaction and scar formation after cardiac ischemia leading to better hemodynamic performance. <i>Life Sciences</i> , 2016, 151, 348-358.	4.3	8
126	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, 122-127.	1.1	65

#	ARTICLE	IF	CITATIONS
127	miRNAâ€221 and miRNAâ€222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. <i>Molecular Oncology</i> , 2015, 9, 1421-1433.	4.6	71
128	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1049-1057.	1.1	85
129	Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases. <i>Experimental and Molecular Pathology</i> , 2015, 99, 682-686.	2.1	12
130	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , 2015, 524, 47-53.	27.8	1,634
131	Rationale, design and objectives of ARegPKD, a European ARPKD registry study. <i>BMC Nephrology</i> , 2015, 16, 22.	1.8	46
132	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. <i>BMC Cancer</i> , 2015, 15, 291.	2.6	7
133	<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung. <i>Clinical Cancer Research</i> , 2015, 21, 907-915.	7.0	155
134	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015, 526, 700-704.	27.8	478
135	Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing. <i>PLoS ONE</i> , 2015, 10, e0129544.	2.5	23
136	<i>ROS1</i> rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. <i>Oncotarget</i> , 2015, 6, 10577-10585.	1.8	85
137	The LIM-Only Protein FHL2 Reduces Vascular Lesion Formation Involving Inhibition of Proliferation and Migration of Smooth Muscle Cells. <i>PLoS ONE</i> , 2014, 9, e94931.	2.5	17
138	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014, 5, 3518.	12.8	239
139	<i>CD74</i> â€“ <i>NRG1</i> Fusions in Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2014, 4, 415-422.	9.4	238
140	Changing Histopathological Diagnostics by Genome-Based Tumor Classification. <i>Genes</i> , 2014, 5, 444-459.	2.4	12
141	Comparison of TNM-based stage grouping versus UICC/AJCC stage grouping (7th edition) in malignant parotid gland tumors. <i>Oral Oncology</i> , 2013, 49, 903-910.	1.5	14
142	Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. <i>Genome Biology</i> , 2013, 14, r137.	9.6	78
143	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	21.4	1,186
144	Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. <i>BMC Clinical Pathology</i> , 2012, 12, 13.	1.8	63

#	ARTICLE	IF	CITATIONS
145	Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. International Journal of Cancer, 2012, 131, 2704-2709.	5.1	118